1700010L13Rik Inhibitors
Chemical inhibitors of the protein 1700010L13Rik represent a diverse group of compounds that target various signaling pathways in which this protein is involved. Staurosporine, a potent kinase inhibitor, can disrupt numerous protein kinases, thereby inhibiting 1700010L13Rik's activity within those kinase-regulated pathways. Similarly, Bisindolylmaleimide I, as a protein kinase C (PKC) inhibitor, can downregulate 1700010L13Rik signaling by impairing PKC-mediated pathways. LY294002, known for its specificity in inhibiting PI3K, can obstruct the PI3K/Akt pathway that is associated with the protein's function. By doing so, LY294002 prevents the activation cascade that would normally enhance 1700010L13Rik's activity. Furthermore, PP2, by selectively inhibiting Src family tyrosine kinases, can alter signaling pathways dependent on tyrosine kinase activity, which are crucial for 1700010L13Rik's role in the cell.
In addition to the above, PD98059 and U0126, both MEK inhibitors, can impede the MAPK/ERK pathway's function, thereby inhibiting the involvement of 1700010L13Rik in these signaling processes. SB203580, which targets p38 MAP kinase, can similarly inhibit pathways essential for 1700010L13Rik's activity by blocking p38 MAPK. Rapamycin, an mTOR inhibitor, can disrupt mTOR signaling pathways, which are key to the regulation of 1700010L13Rik. SP600125, a JNK inhibitor, can impede the JNK signaling pathway and thus the activity of 1700010L13Rik if its function is regulated by JNK signaling. Wortmannin, another PI3K inhibitor, can also disrupt the PI3K/Akt signaling pathway, leading to the inhibition of 1700010L13Rik. Lastly, Y-27632, a ROCK inhibitor, can hinder the Rho/ROCK pathway, which could be integral to 1700010L13Rik's role, while PD173074, an inhibitor of FGFR, can interfere with signaling pathways that involve 1700010L13Rik, particularly if FGFR signaling plays a part in the regulation of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases. Considering that 1700010L13Rik functions within specific kinase-related signaling pathways, staurosporine can inhibit these pathways, thereby directly inhibiting the functional activity of 1700010L13Rik. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). Since 1700010L13Rik is involved in pathways regulated by PKC, the inhibition of PKC can lead to a decrease in 1700010L13Rik signaling, thereby inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. By inhibiting PI3K, LY294002 can disrupt the PI3K/Akt pathway, which is known to be associated with 1700010L13Rik function. Disruption of this pathway can lead to the direct inhibition of 1700010L13Rik's activity within the cell. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting these kinases, PP2 can affect the signaling pathways that involve 1700010L13Rik, which are dependent on tyrosine kinase activity, thereby inhibiting 1700010L13Rik's functional role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can disrupt the MAPK/ERK pathway. As 1700010L13Rik operates within this pathway, inhibiting MEK leads to a reduction in ERK activation, which in turn inhibits the functional role of 1700010L13Rik in cellular signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. It can inhibit the p38 MAPK pathway, which may be crucial for the function of 1700010L13Rik. By inhibiting p38 MAPK, SB203580 can restrict the signaling pathway, leading to the inhibition of 1700010L13Rik's activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK kinase. By blocking this pathway, U0126 can inhibit the functional activity of 1700010L13Rik, which is known to interact with components of the MAPK/ERK signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and by inhibiting mTOR, it can disrupt signaling pathways that are crucial for the function of 1700010L13Rik. The mTOR pathway is a key regulator of cell growth and metabolism, and its inhibition can lead to the functional inhibition of 1700010L13Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibition of the JNK pathway can lead to reduced activity of 1700010L13Rik if JNK signaling is involved in its functional regulation or activation. Therefore, SP600125 can result in the functional inhibition of 1700010L13Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, Wortmannin disrupts the PI3K/Akt pathway, which in turn can inhibit the functional activity of 1700010L13Rik, especially if this protein’s activity is regulated by signaling through this pathway. | ||||||